several studies have been reported piperacillin-tazobactam (TAZ/PIPC)-associated AKI with various frequencies. The aim of this study was to determine the frequency of TAZ/PIPC-associated AKI among our patients and to identify the risk factors for this clinical entity. this retrospective cross-sectional study was conducted at Hamad General Hospital; it involved adult patients who were admitted from January 2017 to December 2017. we involved 917 patients, of whom 635 (69.25%) were males and 282 (30.75%) were females. The mean age of the patients was 52 (SD 19) years, and 98 (10.7%) patients were diagnosed with AKI. The patients with AKI were significantly older than without AKI [59.71 (SD 19.79) versus 51.06 (SD 18.67); P< 0.001]. After TAZ/PIPC initiation, the mean creatinine level in the AKI group was higher than the mean creatinine level in the non-AKI group,[158.91 (SD 81.93) versus 66.78 (SD 21.42); P< 001]. The mean time of onset of AKI after PIPC/TAZ initiation was 4.46 (SD 3.20)(1-12 days). AKI was significantly associated with low mean serum albumin (P< 0.001), high mean fasting blood glucose (P< 0.001), coronary artery diseases (P< 0.001), heart failure (P< 0.001), liver diseases (P= 0.047), diabetes mellitus (P= 0.021) and hypertension (P< 0.001). The in-hospital mortality was significantly higher in the AKI group [38.78% versus 5.13% in the non-AKI group; P< 0.001], and only advanced age and heart failure were found as independent risk factors for TAZ/PIPC-associated AKI. TAZ/PIPC was significantly associated with AKI. Advanced age and heart failure were identified as independent risk factors for TAZ/PIPC-associated AKI.